Table 2 Quality indicators for all patients evaluated
N | Indicator | Patients evaluated by the indicator | Patients who met the indicator | Standard set by GeSIDA | Compliance with the indicator in the study | |||
|---|---|---|---|---|---|---|---|---|
(N) | (N) | (%) | (CI 95%) | (%) | ||||
1 | Specialized doctor care | 100 | 100% | Yes | ||||
2 | Availability of diagnostic resources | 100 | Yes (all) | Yes | ||||
3 | External pharmacy for dispensing drugs | No | Yes | No | ||||
4 | Conditions of privacy and structural confidentiality | 100 | 100% | Yes | ||||
6 | Delay in referral to specialized care | 47 | 42 | 89.4 | 76.9 | 96.5 | 100% | No |
7 | Late diagnosis of HIV in specialized care | 106 | 28 | 26.4 | 18.3 | 35.9 | < 25% | Yes |
8 | HIV diagnosis with previous negative serology | 106 | 64 | 60.4 | 50.4 | 69.7 | 80% | No |
10 | Complementary tests in the initial assessment | 334 | 322 | 96.4 | 93.8 | 98.1 | 95% | Yes |
11 | HIV plasma viral load | 334 | 334 | 100 | 98.9 | 100 | 100% | Yes |
12 | Determination of lymphocyte subpopulations (CD4) | 334 | 334 | 100 | 98.9 | 100 | 100% | Yes |
13 | Health education at initial assessment | 332 | 187 | 56.3 | 50.8 | 61.7 | 95% | No |
15 | Indication of treatment with < 350 CD4 and without prior ART | 117 | 3 | 2.6 | 0.5 | 7.3 | < 10% | Yes |
16 | Periodicity of visits (regular follow-up) | 218 | 193 | 88.5 | 83.5 | 92.4 | 85% | Yes |
17 | Basic renal study in HIV+ patients | 212 | 209 | 98.6 | 95.9 | 99.7 | 100% | Yes |
20 | LTI detection | 189 | 110 | 58.2 | 50.8 | 65.3 | 90% | No |
21 | Vaccination against hepatitis A | 58 | 54 | 93.1 | 83.3 | 98.1 | 85% | Yes |
22 | Vaccination against hepatitis B | 88 | 81 | 92.0 | 84.3 | 96.7 | 85% | Yes |
23 | Vaccination against pneumococcal infection | 213 | 193 | 90.6 | 85.9 | 94.2 | 85% | Yes |
24 | Prophylaxis against Pneumocystis jirovecii and Toxoplasma | 42 | 41 | 97.6 | 87.4 | 99.9 | 100% | Yes |
25 | Treatment and prevention of smoking | 93 | 67 | 72.0 | 61.8 | 80.9 | 95% | No |
26 | Alcohol intake assessment | 218 | 8 | 3.7 | 1.6 | 7.1 | 95% | No |
29 | Syphilis screening | 149 | 68 | 45.6 | 37.5 | 54.0 | 70% | No |
30 | LTI treatment | 25 | 23 | 92.0 | 74.0 | 99.0 | 95% | Yes |
31 | Loss to follow-up | 255 | 14 | 5.5 | 3.0 | 9.0 | ≤ 5% | Yes |
32 | Recovery of failed appointments | 84.9 | 85% | Yes | ||||
35 | Adaptation of initial ART to the guidelines | 119 | 119 | 100 | 96.9 | 100 | 95% | Yes |
36 | Initiation of ART in patients with symptomatic B/C events | 33 | 32 | 97.0 | 84.2 | 99.9 | 90% | Yes |
37 | First visit after the establishment of ART | 117 | 108 | 92.3 | 85.9 | 96.4 | 90% | Yes |
38 | Undetectable viral load (< 50 copies/ml) at week 48 | 106 | 102 | 96.2 | 90.6 | 99.0 | 80% | Yes |
39 | Treatment with Abacavir (ABC) without previous HLA-B 5701 | 77 | 0 | 0 | 0 | 4.7 | 0% | Yes |
40 | Treatment changes during the first year | 98 | 20 | 20.4 | 12.9 | 29.7 | < 30% | Yes |
41 | Record of adherence to treatment | 312 | 266 | 85.3 | 80.8 | 89.0 | 95% | No |
42 | Study of resistance in case of virologic failure | 45 | 41 | 91.1 | 78.8 | 97.5 | 90% | Yes |
44 | Average expenditure per patient in first treatment | 13 | 8710.8* | ** | Yes | |||
45 | ART in pregnant women with HIV | 17 | 17 | 100 | 80.5 | 100 | 100% | Yes |
47 | Vertical transmission incidence | 17 | 0 | 0 | 0 | 19.5 | < 1% | Yes |
49 | Evaluation by CHILD or MELD for chronic liver disease | 12 | 6 | 50.0 | 21.1 | 78.9 | 100% | No |
50 | Evaluation of hepatitis C virus coinfection | 7 | 7 | 100 | 59.0 | 100 | 90% | Yes |
54 | HBsAg patients receiving effective treatment | 12 | 12 | 100 | 73.5 | 100 | 90% | Yes |
55 | Ultrasound control in cirrhotic patients | 8 | 4 | 50.0 | 15.7 | 84.3 | 90% | No |
56 | Cardiovascular risk assessment | 212 | 120 | 56.6 | 49.6 | 63.4 | 90% | No |
58 | Patients with discharge report after hospitalization | 80 | 80 | 100 | 95.5 | 100 | 100% | Yes |
59 | Reports of discharge of deceased patients in the hospital | 12 | 12 | 100 | 73.5 | 100 | 100% | Yes |
60 | Follow-up in outpatient clinic after hospital discharge | 74 | 74 | 100 | 95.1 | 100 | 100% | Yes |
62 | Overall mortality rate in patients in follow-up | 334 | 15 | 11.7 | 8.7 | 24.9 | ≤ 25*** | Yes |
63 | Mortality rate due to AIDS-related causes | 334 | 3 | 3.2 | 1.0 | 9.8 | Not established | |
64 | Continuing education | 100 | 75% | Yes | ||||